Pharmaceutical Technology23m
USPTO grants patent to Vistagen’s neuropathic pain treatment
The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.
gla.ac.uk2h
New research seeks to find new ways to target opioid addiction
An international team of researchers, led by the University of Glasgow, hopes to find new ways to target opioid addiction ...
Science Daily8h
Beyond the gut: A new frontier in IBS treatment by targeting the brain
Irritable bowel syndrome (IBS) is a common digestive disorder with unclear causes, affecting about 10% of the global population. Researchers have now discovered that opioid delta-receptor agonists may ...
Tolerance11h
First new non-opioid painkiller approved in the US for decades – here’s how it works
The FDA has approved suzetrigine, a groundbreaking non-opioid painkiller that targets pain at its source, offering a safer, addiction-free pain-relief treatment.
Armed robbery in Revesby16h
US Approves First New Non-Opioid Painkiller in Decades
A new non-opioid painkiller, suzetrigine , has just been approved by the US drug regulator, the FDA. It is the first non-opioid painkiller the agency ...
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, ...
EurekAlert!21h
Overview of the study: Opioid delta-receptor agonists alleviate stress-induced IBS symptoms via the insular cortex (IMAGE)
Using an innovative and recently validated animal model of IBS, the researchers showed that opioid delta-receptor agonists can ameliorate stress-induced IBS symptoms by acting on the insular cortex of ...